Vitamin D in the treatment of multiple sclerosis: A meta-analysis
J Neurol Neurosurg Psychiatry 2017;88:e1.
Laurie Mclaughlin1,2, Laura Clarke1,2, Elham Khalilidehkordi1,2, Helmut Butzkueven3, Bruce Taylor4, Simon Broadley1,2
The articles in both of the categories MS and Meta-Analysis are:
- Fewer Multiple Sclerosis lesions when supplemented with Vitamin D – meta-analysis May 2017
- Multiple Sclerosis and small doses of Vitamin D – meta-review March 2016
- Multiple sclerosis patients have 15 ng lower levels of vitamin D – meta-analysis June 2014
- Multiple Sclerosis and the Vitamin D Receptor – meta-analysis July 2014
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- No association between Multiple Sclerosis relapses and being treated with vitamin D–meta-analysis May 2013
- Multiple Sclerosis 23 percent more likely if born in April vs. Oct – meta-analysis Nov 2012
MS Intervention using Vitamin D:
- Multiple Sclerosis Relapsing-Remitting rate reduced 30 percent by addition of 14,000 IU vitamin D daily – RCT Nov 2016
- Vitamin D has already cleared 100 percent of lesions from over 1,000 MS patients in Brazil
- Dr. Coimbra explains his treatment with high dose vitamin D for multiple sclerosis – Feb 2015
- No multiple sclerosis relapses during pregnancy if 50,000 IU of Vitamin D weekly – RCT April 2015
- 1000 IU per kg Vitamin D for autoimmune diseases – Coimbra Aug 2013
- Optic neuritis progession into Multiple Sclerosis reduced 68 percent by 50,000 IU of vitamin D weekly
- Video by Dr. Coimbra – 95 percent of auto-immune cured with vitamin D in high doses - April 2014
- Autoimmune disorder patients in Brazil helped by vitamin D – video and Facebook – Nov 2012
- Risk of going from pre-MS to MS reduced 68 percent with 7100 IU vitamin D – RCT Dec 2012
- MS helped by average daily 2800 IU vitamin D – RCT Aug 2012
- CureTogether Vitamin D symptoms, treatments, and causes
- Yet again - more than 10000 IU of vitamin D treats MS – July 2011
- Overview MS and vitamin D
Objectives There is an association between latitude, relative vitamin D deficiency and risk of multiple sclerosis (MS). There is some evidence for an association between vitamin D and disease progression. Many neurologists recommend vitamin D supplementation for MS. A number of small trials of vitamin D have been undertaken. We have performed a meta-analysis with the aim of investigating the role of therapeutic vitamin D in relapsing-remitting MS.
Methods A systematic search of databases was performed to identify clinical trials assessing vitamin D in patients with relapsing-remitting MS. Articles were screened independently by two investigators and trials were selected based on inclusion and exclusion criteria. Analysis was performed using RevMan software.
Results Seven studies involving 284 patients were included in the final analysis. All studies involved the use of vitamin D as add-on therapy. Studies were divided into two groups for analysis to improve homogeneity of outcomes: vitamin D dosing versus placebo and high versus low dosing protocols. Results for studies were judged to be at low risk of bias and this was confirmed by funnel plots.
A statistically significant reduction of GAD-enhancing lesions (mean difference −0.98 (95% CI −1.79 to 0.18)) was seen in placebo-controlled studies. There were non-significant trend towards fewer relapses and improvement in EDSS for these studies. Dose comparison studies showed a significant increase in EDSS (mead difference 0.4 (95%CI 0.36 to 0.44)) and non-significant trends of increased annualised relapse rates and GAD-enhancing lesions for the higher dose arms.
Conclusions These findings suggest vitamin D supplementation may have a therapeutic role in the treatment of MS. However, there is uncertainty with regards to the most appropriate dose, with higher dose potentially being associated with worse outcomes. There remains the need for a well performed randomised, dose-comparison, placebo-controlled trial of vitamin D in MS.
http://dx.doi.org/10.1136/jnnp-2017-316074.92 Publisher charges for the PDF